Diltiazem Activates Type III Interferon Pathway to Combat Microbial Resistance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies lack effective compounds to stimulate the expression of type III interferon proteins, which are crucial for preventing and treating infections by pathogenic microorganisms in the respiratory and intestinal tracts without inducing inflammatory responses.

Innovation Solution

Diltiazem, a calcium channel blocker, is found to stimulate the expression of genes encoding type III interferon proteins, activating the expression of interferon-stimulated genes (ISGs) and enhancing the body's antipathogenic response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but antibiotic resistance develops

Engineering Contradiction:

Improvetreatment efficacyVSAvoidantibiotic resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses type III interferons, which are naturally produced by the body as part of the innate immune response, to treat infections. This converts the body's own defense mechanism into a therapeutic agent, avoiding the problem of resistance that plagues conventional antibiotics while maintaining treatment efficacy against both viral and bacterial infections

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The invention changes the therapeutic approach from using exogenous antibiotics that select for resistance to stimulating endogenous type III interferon production, which creates a different mode of action that does not contribute to resistance development while effectively treating infections

Inventive Principle:

Principle #35Parameter changes

2Reliability

If antiviral medications are used to treat viral infections, then viral replication is reduced, but resistance to antivirals emerges

Engineering Contradiction:

Improvetreatment efficacyVSAvoidviral resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent harnesses the body's natural type III interferon response to combat viral infections. By stimulating endogenous production of these interferons rather than administering exogenous antivirals, the treatment leverages a complex, multi-targeted immune response that is far less prone to resistance development compared to single-target antiviral drugs

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

Type III interferons provide broad-spectrum protection against multiple different viruses simultaneously, rather than targeting specific viral mechanisms. This multi-functional approach means that resistance to one virus does not confer resistance to others, and the diverse mechanisms of type III interferon action make it difficult for viruses to develop resistance

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If vaccines are administered to prevent viral infections, then immunity is provided, but delivery schedules and variable efficacy remain issues

Engineering Contradiction:

Improveprotection efficacyVSAvoidvaccination logistics

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent enables the body to produce its own protective type III interferons in response to infection, rather than relying on pre-administered vaccines that require complex scheduling. The therapeutic compound stimulates the body's self-service immune response, providing flexible protection that activates when needed without requiring advance vaccination schedules

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The invention allows for pre-treatment with the compound that stimulates type III interferon production before exposure to pathogens, creating a state of heightened immune readiness. This preliminary activation of the interferon response system provides protection without requiring the rigid scheduling constraints of traditional vaccines

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Diltiazem effectively activates the type III interferon pathway, leading to increased expression of type III interferons and ISGs, which enhances the antimicrobial response and reduces the replication of pathogens such as respiratory syncytial virus, parainfluenza virus, and Pseudomonas aeruginosa.

Implementation Method 1

Diltiazem, a calcium channel blocker, is found to stimulate the expression of genes encoding type III interferon proteins, activating the expression of interferon-stimulated genes (ISGs)

Methodology Applied

Scientific EffectGene expression activation:

Implementation Method 2

Diltiazem is a molecule of the benzothiazepine family... Its known physiological action is the inhibition of calcium channels, and thus the inhibition of intracellular calcium flow

Methodology Applied

Scientific EffectCalcium channel blocking:

Data Source

PatentUS12285433B2Diltiazem for use in the treatment of microbial infections

Publication Date: 2025.04.29 UNIVERSITE LAVAL

AI summary

The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and/or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and/or intestinal tracts.